CMOs are exploring the potential of mammalian cell culture production amidst soaring demand for biopharmaceutical contract manufacturing services. Incumbents, such as Charles River and Lonza have furthered investments in mammalian cells. To illustrate, in May 2021, Lonza announced pouring USD 936 million to bolster the footprint of mammalian drug substance manufacturing sites in the U.S. and Switzerland.
Biopharmaceutical firms are responding to the demand for outsourced services with bullish investments in research activities. For instance, in July 2022, Wuxi Biologics contemplated expanding its large-scale drug product & drug substance manufacturing capabilities and R&D in Singapore.
Adoption of Contract Development & Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) with surging demand for Monoclonal Antibodies (MAbs) products will boost the market share. The final report, along with the database, will peruse the following dynamics:
• Insights on commercial availability and annual approvals of MAb products.
• Commercially available biopharmaceuticals and biologics produced using mammalian cell lines.
• Competitive landscape with industry developments.
• CMO Mapping of 88 companies.
Get your copy or request a free sample of the report “Biopharmaceutical CMO & CRO Production Capacity Study,” compiled and published by Grand View Research.
Biopharmaceutical CMO & CRO Production Capacity Report Scope
|
CMO
Capacity mapping (for 88 companies) |
|
Key
Players: Location Mapping & existing Capacities |
|
Recent expansions/ Future plans |
|
Comparative
Heat Map |
